Position in NVAX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$542,158
+$32,253 QoQ
Shares Held
57,554
-8.1% QoQ
Ownership
0.035%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#89
of 263 holders
Holding Since
Mar 2021
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Thrivent Financial for Lutherans holds $348,973,073 across 50 Biotechnology names. NVAX ranks #41 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
1,620,743 | $88,184,625 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
131,457 | $81,968,697 | |
| 3 | RPRX |
Royalty Pharma plc
|
740,772 | $41,535,085 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
80,500 | $19,398,084 | |
| 5 | ARGX |
Argenx SE
|
12,688 | $11,771,545 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
20,169 | $10,018,546 | |
| 7 | VCEL |
Vericel Corp
|
170,272 | $7,575,400 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
17,229 | $6,403,502 |
All Filings in NVAX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $542,158 | 57,554 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $509,905 | 62,642 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $514,664 | 76,587 | Shares | Sole | 2026-02-05 | |
| 2025-06-30 | $1,320,738 | 209,641 | Shares | Sole | 2025-08-26 | |
| 2021-03-31 | $6,798,036 | 37,494 | Shares | Defined | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||